Future of idiotypic vaccination for B-cell lymphoma

Expert Review of Vaccines

Volumn 8, Issue 1, 2009, Pages 43-50

  De Cerio, Ascensión López Díaz ^a   Inogés, Susana ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Clinical trial; Idiotype; Lymphoma; Vaccine

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; IMMUNOLOGICAL ADJUVANT; PREDNISONE; RITUXIMAB;

B CELL LYMPHOMA; CANCER IMMUNIZATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLICULAR LYMPHOMA; HUMAN; IDIOTYPIC VACCINATION; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; VACCINATION;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, B-CELL; TREATMENT FAILURE; TREATMENT OUTCOME; VACCINATION;

EID: 58149481711     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.8.1.43     Document Type: Review

References (34)

1. Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev. Anticancer Ther. 1, 65-72 (2001).
2. McCarty H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br. J. Haematol. 123, 770-781 (2003).
3. Bendandi M. The role of idiotype vaccines in the treatment of human B-cell malignancies. Expert Rev. Vaccines 3, 163-170 (2004).
4. Harris JR, Markl J. Keyhole limpet hemocyanin: molecular structure of a potent marine immunoactivator. A review. Eur. Urology 37(Suppl. 3), 24-33 (2000).
5. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad. Sci. USA 93, 10972-10977 (1996).
6. López-Díaz de Cerio A, Zabalegui N, Rodríguez- Calvillo M et al. Anti-idiotype antibodies in cancer treatment. Oncogene 26, 3594-3602 (2007).
7. Bendandi M. Aiming at a curative strategy for follicular lymphoma. CA Cancer J. Clin. 58(5), 305-317 (2008). • Systematic review on follicular lymphoma with a new proposal of cure definition for this disease.
8. Neelapu SS, Kwak LW, Kobrin CB et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 11, 986-991 (2005).
9. Bertinetti C, Zirlik K, Heining-Mikesch K et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res. 66, 4496-4502 (2006).
10. McCormick AA, Reddy S, Reinl SJ et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a Phase I clinical study. Proc. Natl Acad. Sci. USA 105, 10131-10136 (2008).
11. Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B-cell tumors. J. Immunol. Methods 89, 61-72 (1986).
12. Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A et al. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit. Rev. Oncol. Hematol. 52, 1-7 (2004).
13. Hurvitz SA, Timmerman JM. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr. Opin. Oncol. 17, 432-440 (2005).
14. Kanter G, Yang J, Voloshin A et al. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood 109, 3393-3399 (2007).
15. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209-1215 (1992). • First formal proof of biological efficacy of any human cancer vaccine.
16. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89, 3129-3135 (1997).
17. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5, 1171-1177 (1999). • First formal proof of clinical efficacy of any human cancer vaccine.
18. Barrios Y, Cabrera R, Yáñez R et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 87, 400-407 (2002).
19. Santos C, Stern L, Katz L et al. BiovaxIDTM vaccine therapy of follicular lymphoma in first remission: long-term follow-up of a Phase II trial and status of a controlled, randomized Phase III trial. Blood 106(Suppl. 1), 2441a (2005).
20. Inogés S, Rodríguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in follicular lymphoma. J. Natl Cancer Inst. 98, 1292-1301 (2006). • First formal proof of clinical benefit of any human cancer vaccine.
21. Longo DL. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J. Natl Cancer Inst. 98, 1263-1265 (2006).
22. Bendandi M. Clinical benefit of idiotype vaccines: too many trials for a clever demonstration? Rev. Recent Clin. Trials 1, 67-74 (2006). • Predicts failure of all randomized trials on idiotypic vaccination 2 years before actual failure.
23. Neelapu SS, Gause BL, Nikcevich DA et al. Phase III randomized trial of patientspecific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. Clin. Lymphoma 6, 61-64 (2005).
24. Forstpointner R, Dreyling M, Repp R et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104, 3064-3071 (2004).
25. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105, 1417-1423 (2005).
26. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106, 3725-3732 (2005).
27. Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J. Clin. Oncol. 25, 1986-1992 (2007).
28. Vose JM. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematol. Oncol. 24, 47-55 (2006).
29. Weng WK, Czerwinski D, Timmerman J et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22, 4717-4724 (2004).
30. Yáñez R, Barrios Y, Ruiz E et al. Anti-idiotypic immunotherapy in follicular lymphoma patients: results of a long follow-up study. J. Immunother. 31, 310-312 (2008).
31. Biovest International press release www.vcall.com/ic/genrelease. asp?id=132297102 Corporateir.net http://media.corporateir.net/media_files/irol/ 14/142124/gtop_ phase3resultssummary.pdf
32. Favrille cancer treatment www.favrille.com/trials/phase-3-clinicaltrial- summary.htm
33. Clinicaltrials.gov search results www.clinicaltrials.gov/ct2/results? term=idi otype+vaccine+lymphoma
34. Clincaltrials.gov (FLIDVAX2006) www.clinicaltrials.gov/ct2/show/nct00530 140?term=idiotype+navarre&rank=1